eClinical Technology and Industy News

Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Virology Trial of AT-527 in Outpatient Setting

Excerpt from the Press Release:

BOSTON, Feb. 04, 2021 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the first patient has been dosed in the Phase 2 virology trial evaluating AT-527 in mild or moderate COVID-19 patients in an outpatient setting. The trial will enroll patients in the United Kingdom (UK), Ireland and other countries. AT-527 is an orally administered, direct-acting developmental antiviral agent derived from Atea’s purine nucleotide prodrug platform.

“In collaboration with Roche, we are initiating a randomized virology study in the UK and Ireland, where COVID-19 is fast-spreading and an estimated 30-40% of new infections involve a new mutation. This study presents the opportunity to investigate the antiviral activity of AT-527 in these patients. Importantly, this study is evaluating patients in an outpatient setting, which is the anticipated patient population of the upcoming Phase 3 trial,” said Jean-Pierre Sommadossi, Ph.D., Founder and Chief Executive Officer of Atea Pharmaceuticals. “While vaccines will play an important role in controlling the COVID-19 pandemic, we need additional treatment options to stay ahead of the virus, and direct-acting antivirals have the potential to be an essential complement to vaccines.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary Data Management

Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives